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Summary  
The time course of regional mouse brain distribution of radioactivity after i.v. 
injection of a tracer dose of [11C]tetrabenazine ([11C]TBZ) has been determined. 
Radiotracer uptake into brain is rapid, with 3.2% injected dose in the brain at 2 
min. Egress from the brain is also very rapid, with only 0.21% of the injected 
dose still present in brain at 60 min. Radiotracer washout is slowest from the 
striatum and hypothalamus, consistent with binding to the higher numbers of 
vesicular monoamine transporters in those brain regions. The rank order of 
radioligand binding at 10 min after injection is striatum > hypothalamus > 
hippocampus > cortex = cerebellum, similar to that found using in vitro assays of 
the vesicular monoamine transporters. Maximum ratios of striatum/cerebellum and 
hypothalamus/cerebellum were 2.85 + 0.52 and 1.69+ 0.25, respectively, at 10 
min after injection. Co-injection of unlabeled tetrabenazine (10 mg/kg) or 
pretreatment with reserpine (1 mg/kg i.p., 24 h prior) was used to demonstrate 
specific binding of radioligand in striatum, hypothalamus, cortex, hippocampus and 
cerebellum. Distribution of [llC]TBZ was unaffected by pretreatment with the 
neuronal dopamine uptake inhibitor GBR 12935 (20 mg/kg i.p., 30 min prior). 
[11C]Tetrabenazine is thus a promising new radioligand for the in vivo study of 
monoaminergic neurons using Positron Emission Tomography. 
In vivo imaging and quantification of neuronal losses in living human brains would be of 
great utility for the understanding of the development and progression of neurodegeneration in 
Parkinson's disease. Numerous potential neuronal imaging agents based on the neuronal 
monoamine reuptake system have been developed, and several of these ([11C]nomifensine (1), 
[11C]cocaine (2), and [18F]GBR 12909 (3)) are currently being evaluated in human subjects. 
The imaging of vesicular neurotransmitter uptake sites would form an alternative method for 
quantitation of neuronal densities, and the feasibility of such imaging using carbon-11 and 
fluorine-18 labeled inhibitors of vesicular acetylcholine transport has been demonstrated by 
ourselves (4) and others (5) using derivatives of vesamicol. Tetrabenazine (TBZ) and 
structurally related benzoquinolines comprise a class of compounds which are high affinity 
inhibitors (6) for the vesicular monoamine transporters and which exhibit shorter duration of 
action as compared to reserpine (7). Although the benzoquinolines are not selective for 
dopaminergic vesicular transporters using in vitro assays, TBZ does deplete dopamine to a 
greater extent than serotonin and norepinephrine (8,9). [3H]Dihydro te t rabenaz ine  
([3H]TBZOH), a simple reduction product from tetrabenazine, has been recently utilized as an in 
vitro marker for monoaminergic neurons in brain regions (6,10-15). In 6-hydroxydopamine 
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lesioned rats, loss of striatal [3H]TBZOH binding sites correlated well with loss of tyrosine 
hydroxylase activity (14), and reductions of [3H]TBZOH binding sites in the caudate-putamen of 
post-mortem Parkinsonian brains are extensive (73-87%) (15). These in vitro results suggest 
that the binding of radioligands for vesicular monoamine transporters may serve as an excellent 
measure of losses of dopaminergic neurons in degenerative diseases. To extend this approach to 
in vivo imaging with Positron Emission Tomography (PET), we have developed a synthesis of 
[11C]tetrabenazine ([11C]TBZ) and have begun the process of preclinical animal evaluation of 
this exciting new radioligand. We report here the time course and pharmacological blocking of 
the specific binding of [ 11 C]tetrabenazine in mouse brain. 
Methods  
Chemicals 
No-carrier-added, high-specific-activity [llC]tetrabenazine was prepared by O- 
[11C]methylation of 9-desmethyltetrabenazine, by a procedure to be reported elsewhere (16). 
The product was dissolved in isotonic phosphate buffer (pH 6.0) for injection. Specific activity 
at time of injection was >I000 Ci/mmol as determined by analytical HPLC. 
Tetrabenazine was obtained from Fluka, and prepared for injection by dissolution in 4% 
ethanol: isotonic phosphate buffer, pH 4.5. Reserpine was obtained from Sigma Chem. Co. and 
prepared for injection as a solution containing 250 mg reserpine, 2 ml benzyl alcohol, 250 mg 
citric acid, 10 ml Tween-80 and 100 ml sterile water. GBR 12935 methanesulfonate (obtained 
from Gist-Brocades, Inc.) was dissolved in 5% ethanol : isotonic saline solution. 
Regional Brain and Whole Organ Distributions 
In vivo tissue distribution studies were performed in female CD-1 mice, 20-27 g 
(Charles River). For each data point 4 animals were used. Animals were anesthetized with 
diethyl ether and [11C]TBZ (0.02 - 0.57 mCi in 0.05 to 0.1 ml) injected via the tail vein. The 
animals were allowed to recover, then sacrificed by decapitation at 2,5,10,20,30,40 or 60 min 
after injection. A blood sample was collected, and the brain rapidly removed and dissected into 
samples of striatum, cortex, hippocampus, hypothalamus and cerebellum. The heart, lungs, 
adrenals and rest of brain were also removed. All samples were counted for carbon-11 (Packard 
5780 gamma-counter) and then weighed. Data were calculated as % injected dose per gram 
(%ID/g) of tissue, and %ID/organ for brain, heart, adrenals and lungs. 
Pharmacological Comoetition Studies 
Pharmacological competition studies were done using co-injection of tetrabenazine (10 
mg/kg, i.v) and [11C]TBZ, or by pretreatment of the animals with reserpine (1 mg/kg, i.p., 24 h 
prior) or GBR 12935 (20 mg/kg i.p., 30 rain prior) followed by injection of [ l lC ]TBZ.  
Experiments were done using groups of four animals per study (total N = 12 for TBZ). For all 
competition studies, control animals (total N = 32) were also studied using an iniection of high 
specific activity [ l lC]TBZ.  Regional brain distributions and organ distributions were 
determined as described above. 
Data were analyzed for significance using an unpaired Student's t-test. 
Resul t s  
The time course of regional brain distribution of [11C]TBZ following i.v. injection is 
shown in Fig. 1. In all brain areas, radioactivity levels were highest at the earliest time point 
measured (2 min) and declined rapidly in all regions over the 60 min period. Radiotracer 
washout was slowest from the striatum and hypothalamus (Fig. 1A), consistent with specific 
binding to the highest numbers of vesicular monoamine transporters in those brain regions. The 
time-tissue activity curves for hippocampus, cortex and cerebellum were very similar, and after 
about 10 minutes paralleled the blood curve although they remained slightly higher (Fig. 1B). At 
the 10 minute point, hippocampus, hypothalamus and thalamus showed higher radiotracer 
concentrations (p < 0.05) than did cerebellum. Maximum tissue contrasts (striatum/cerebellum, 
STR/CER; and hypothalamus/cerebellum, HYPO/CER) were observed at I0 min after injection, 
therefore this time point was chosen for pharmacological competition studies. 
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TABLE I 
Effect of Treatment With Tetrabenazine, Reserpine and GBR 12935 on Regional Brain 
Distribution of [11C]TB Z in Mice, 10 min After Injection a 
Control TBZh Reserpine c GB 12935 d 
N = 3 2  N = 1 2  N = 4  N = 4  
Re~ion 
striatum 4.96 + 1.0" 
cortex 1.91 + 0.34 
hippocampus 2.01 + 0.36** 
hypothalamus 2.96 + 0.61" 
cerebellum 1.76 + 0.36 
thalamus 2.06 + 0.59** 
pons-medulla 1.96 + 0.30 
blood 1.59 + 0.26 
Region Ratios 
STR/CER 2.85 + 0.52 
HYPO/CER 1.69 + 0.25 
STR/CTX 2.63 + 0.52 
HYPO/CTX 1.55 + 0.20 
Organ 
v 
brain 2.18 + 0.41 
heart 2.54 + 0.17 
adrenal 7.30 + 1.01 
lung 2.44 + 0.33 
1.54 + 0.37*** 2.80 + 0.25*** 5.44 + 0.57 
1 .50+0.35  *** 1.95 + 0 . 3 6  2.01 +0 .19  
1 .50+0.36  *** 1 .65+0 .40  *** 2 . 1 7 + 0 . 1 6  
1 .40+0.33 *** 2.16 + 1.48"** 3 . 2 0 + 0 . 4 1  
1.52 + 0.37**** 3.44 + 2.38*** 1.76 + 0.22 
N.D. N.D. N.D. 
1.77 + 0.25 N.D. N.D. 
1.44-+- 0.27 1.67 + 0.24 1.72 + 0.17 
1.02 + 0.06*** 1.40 + 1.10"** 3.10 + 0.20 
0.93 + 0.07*** 0.71 + 0.98*** 1.82 + 0.19 
1 .03+0.05 *** 1 .49+0 .38  *** 2.71 +0 .18  
0 .94+0 .09  *** 0 .65+0 .38  *** 1 .59+0.19  
1.53 + 0.36*** 2.02 + 0.33 N.D. 
2.52 + 0.67 3.05 + 0.29 N.D. 
6.42 + 1.74 7.29 + 4.89 N.D. 
2.86 + 0.54 3.31 + 1.36 N.D. 
a Results are expressed as % injected dose per gram of tissue (%ID/g) + standard deviation 
b Animals were coinjected with 10 mg/kg of unlabeled TBZ (i.v.). 
Animals were pretreated with 1 mg/kg of reserpine, i.p., .24 h prior to radiotracer 
injection. 
~l Animals were pretreated with 20 mg/kg GBR 12935, i.p., 30 min prior to radiotracer 
injection. 
* p < 0.001 compared to control cerebellum. 
** p < 0.05 compared to control cerebellum. 
*** p <0.001 compared to controls. 
**** p < 0.06 compared to control. 
N.D. Not determined. 
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FIG.  1 
T ime course of  regional  brain uptake of  [ 1 l C ] T B Z  fol lowing 
i.v. iniection.  Values  shown are means  + S.D. (N = 4). 
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FIG. 2. 
Time course of [11C]TBZ in brain, heart, lung and adrenals after i.v. injection. 
The effects of co-injection of 10 mg/kg unlabeled TBZ, pretreatment with 1 mg/kg 
reserpine, or pretreatment with 10 mg/kg GBR 12935 on the regional brain distribution of 
[11C]TBZ are summarized in Table I. Specific binding of [11C]TBZ in striatum, hypothalamus, 
cortex, hippocampus and cerebellum was significantly blocked by coinjection of TBZ. 
Statistically significant reductions of radioligand concentrations in striatum, hippocampus and 
hypothalamus were observed after reserpine pretreatment. In the reserpine treated animals there 
was also a variable increase in radioactivity concentration in the cerebellum as compared to 
controls. Treatment with reserpine or TBZ did not affect blood radioactivity levels. As expected, 
pretreatment with 20 mg/kg GBR 12935, a high affinity inhibitor of the neuronal dopamine 
transporter, had no effect on the levels of [11C]TBZ in any brain region or the blood (Table I). 
The time course of [11C]TBZ uptake and clearance in brain, heart and adrenals, tissues 
with potential [11C]TBZ binding sites, and lung, a tissue with no specific sites but an affinity for 
lipophilic amines, is shown in Fig. 2. Very high initial uptake of radiotracer into the adrenals 
was observed. Except for the brain, none of these tissues showed any specific binding at the ten 
min post-injection point which could be blocked with TBZ or reserpine treatment (Table I). 
D i s c u s s i o n  
Tetrabenazine is a specific, high affinity (Ki approx. 3 nM) inhibitor of monoamine 
uptake into vesicles of presynaptic neurons (6,10-13). Previous in vitro and in vivo studies of 
vesicular monoamine transporters have utilized low specific activity [3H]reserpine (7.9-14 
Ci/mmol) (12,17,18) or [3H]dihydrotetrabenazine (10-15 Ci/mmol) (6,10-12,18). The use of the 
carbon-11 labeled tetrabenazine, with a specific activity of greater than 1000 Ci/mmol, allows 
injections of truly tracer amounts of the radioligand. We report here the first in vivo study of 
vesicular monoamine transporters using a high specific activity radioligand, [11C]tetrabenazine, 
as a potential probe of monoaminergic neuronal losses in neurodegenerative diseases. 
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[11C]Tetrabenazine shows rapid brain uptake and the clearance kinetics are similar to that 
previously reported using pharmacological doses of unlabeled tetrabenazine (19). Regional 
pharmacokinetics, however, show a significantly slower clearance of the radioligand from 
striatum and hypothalamus (Fig. 1A), such that at 10 min after injection there is a clear 
preferential retention of the radioligand in these regions (STR/CER = 2.93 + 0.19, HYPO/CER 
= 1.65 +_ 0.08). The rank order of regional brain distribution of [11C]tetrabenazine was 
striatum > hypothalamus > hippocampus > cortex = cerebellum, and was consistent with that 
observed using in vitro assays and [3H]dihydrotetrabcnazine (I 1,12). For the calculation of 
target to non-target ratios, we have used cerebellum as only an approximation of a non-target 
tissue, as it is clear from the literature and this work that specific binding sites for tetrabenazine 
are present in cerebellum (but are the lowest of the tissue studied here). As is commonly 
observed with in vivo studies, the ratios between target and non-target regions (e.g., 
striatum/cerebellum) do not reach that obtained with the in vitro assays. Although the rank order 
of [ l lC]TBZ binding is also consistent with the greater effect of TBZ on the dopamincrgic 
system, such effects cannot at this time be simply ascribed to higher binding of TBZ in the 
striatum. Our rank order of regional tissue binding of [ 11C]TBZ is also similar to that obtained 
with [3H]reserpine (17), but [11C]tetrabenazine has a much higher brain uptake, most likely due 
to the high lipophilicity and high molecular weight of reserpine which may limit its availability to 
the brain and its passage through the blood-brain-barrier. In that regard, although higher 
target/nontarget ratios might be obtained with a radiolabeled derivative of reserpine, this would 
be offset by the long time necessary for washout of non-specific binding and the low count rate 
due to limited radiotracer accumulation in brain, even if labeled with a long half-life radionuclide. 
That the retention of [ l l C ] T B Z  in mouse brain is due to specific binding to 
monoaminergic vesicular sites (predominantly dopaminergic in striatum, serotonergic + 
noradrenergic in others) is supported by the competition studies, where virtually all of the 
retention of radioligand in the various brain regions is blocked by co-injection of unlabeled TBZ 
(e.g., STR/CER = 1.04 __+ .08). Pretreatment with reserpine blocks specific binding in striatum 
(e.g., STR/CER 1.40 +1.10) and in hypothalamus (HYPO/CER = 0.71+_ 0.98). Pretreatment 
with reserpine also causes a variable increase in cerebellar uptake of [11C]TBZ and similar 
variable changes in radioligand uptake may have occurred in other brain regions; for that reason, 
interpretation of radiotracer distribution changes in other tissues is difficult, even though 
statistical changes are also seen in hippocampus and cerebellum but not cortex. By using cortex 
as a "non-target" tissue which does not show the variability of the cerebellum, significant 
reductions of radioligand binding in striatum and hypothalamus are still clearly evident. Changes 
in the blood-brain-barrier (BBB) permeability of radioligands after reserpine pretreatments have 
been noted in other studies (20,21). Such changes in radiotracer delivery complicate 
interpretation of studies in reserpine-treated animals, but the decrease in radiotracer 
concentrations in target regions as observed here would be the opposite of the higher tissue 
concentrations to be expected if radiotracer retention was due solely to increased delivery to the 
brain. Reserpine and tetrabenazine are mutually antagonistic in both in vitro and in vivo assays 
of vesicular monoamine transporters (13). The monoamine transporter of vesicles is believed to 
possess two binding sites, one (R1) of high affinity for reserpine and monoamines but TBZ 
resistant, and the second (TBZ site) of high affinity for TBZ but with lower affinity for reserpine 
and monoamines (18,22). The blocking of [ l lC]TBZ binding by TBZ and reserpine is 
consistent with this model of the vesicular transporter. It is interesting that reserpine did not 
appear to fully block [11C]TBZ binding, but whether this is dose-related, due to variability in 
BBB permeability, or due to existence of transporters with possibly only one binding site cannot 
be determined by this study. As expected, pretreatment of animals with the neuronal dopamine 
uptake inhibitor GBR 12935 (23) does not affect [11C]TBZ distribution in the brain. 
As part of this study we also examined [11C]tetrabenazine pharmacokinetics in peripheral 
tissues which should have vesicular binding sites, such as heart and adrenals, and a non-specific 
organ, the lung. Radioactivity uptake and washout from heart and adrenals was very rapid and 
specific binding of the radioligand in these tissues could not be demonstrated at the 10 min time 
point. Although consistent with the lower peripheral actions of tetrabenazine compared to 
reserpine, we have examined specific binding only at the ten min time point, and thus we cannot 
rule out a pharmacological effect during the initial high uptake of TBZ into these tissues due to 
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binding to noradrenergic neurons (heart) or chromaffin granules (adrenals). The low lung uptake 
is in agreement with the relatively moderate lipophilicity (log P = 2.68) of tetrabenazine (6), and 
is different than other more lipophilic amines that have been prepared as in vivo radioligands. 
[11C]Tetrabenazine shows regional brain kinetics which are substantially different than 
many of the radioligands previously prepared for quantifying neuronal densities in vivo. 
Dopamine uptake inhibitors such as [11C]nomifensine (1) and [18F]GBR 12909 (3) exhibit a 
slow washout of radioactivity from all brain regions, and a relatively slow development of 
adequate target-to-nontarget ratios. [ l lC]MABV ([11C]N-methylaminobenzovesamicol), 
developed for in vivo study of the vesicular acetylcholine uptake sites, shows rapid brain 
penetration and moderately slow clearance from non-target tissues, but little egress from striatum 
of mice (4). In many ways, [11C]TBZ more closely resembles [11C]cocaine, which shows 
rapid brain uptake and rapid brain clearance, with early (t=10-20 min) delineation of striatal 
tissues (2). 
Throughout this study we have not analyzed blood or tissue samples for possible 
radioactive metabolites of [11C]tetrabenazine. The metabolism of tetrabenazine in rabbit, dog 
and man has been published (24); numerous conjugated and unconjugated metabolites were 
observed in the urine, although the rate of formation and proportions of such metabolites were 
not presented. Analyses of blood and brain samples obtained from rodents, and blood samples 
from humans, show the presence of the metabolite dihydrotetrabenazine (TBZOH) following 
administration of a therapeutic dose of TBZ (25). TBZOH is known to be an inhibitor of 
monoamine vesicular transport with nearly the same Ki as TBZ, and furthermore TBZOH can 
clearly cross the blood-brain-barrier and exert pharmacological effects (25). For future 
quantitative pharmacokinetic analyses of this binding site, the rate and proportion of metabolite 
formation following tracer dose injection of [11C]TBZ will have to be determined. Use of TBZ 
itself, however, did allow us to avail ourselves of the large previous literature on the 
pharmacology and pharmacokinetics of TBZ. 
In conclusion, we have performed the first in vivo study of the regional distribution and 
pharmacokinetics of a tracer dose of [ 11C]tetrabenazine following i.v. injection. The regional 
distribution is consistent with binding to monoaminergic nerve terminals, and the kinetics of 
uptake and egress from brain regions are as expected for a short-acting drug. The BBB 
permeability of this drug, and the kinetics of regional brain accumulations, are supportive of 
further development of labeled benzoquinolines as potential neuronal imaging agents. As 
tetrabenazine is a well understood and clinically used drug with low toxicity (7), the use of 
[11C]tetrabenazine or a close structural analog as an in vivo imaging agent for PET should 
provide an important new method for assessment of the loss of neurons in Parkinson's and other 
neurodegenerative diseases. 
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